Art. -Nr.: HY-B1198

Piperonyl butoxide

(Synonyms: ENT-14250)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Piperonyl butoxide (ENT-14250) is a pesticide synergist and food additive. Piperonyl butoxide has adverse effects on reproduction, development and behavior in mice. Piperonyl butoxide can activate c-Jun and ATF-2 in mouse hepatocytes. Piperonyl butoxide is a liver cancer carcinogen in rats and mice.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 51-03-6
Formel: C₁₉H₃₀O₅
Molecular Weight:338.44

Speicherung:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Piperonyl butoxide Chemical Structure

CAS. Nr.: 51-03-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Parasite Isoform-spezifische Produkte anzeigen :

In Vitro

Piperonyl butoxide (25 μg/mL; 24 h) induces phosphorylation of ATF-2 in mouse hepatocytes ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Mouse immortalized hepatocyte cell line TLR-3
Concentration:

25 μg/mL
Incubation Time:

24 h
Result:

Significantly increased the phosphorylation level of ATF-2.

In Vivo

Piperonyl butoxide (0.6% in diet; Feed administration; 48 h) can activate c-Jun and ATF-2 in mouse hepatocytes, which may promote cell proliferation in the early stage of mouse liver cancer^[1].
Piperonyl butoxide (0.025-0.4% in diet; Feed administration; 8 weeks) can adversely affect the exploratory behavior of female mice^[2]
Pharmacokinetic Analysis in female C57BL/6J mice^[4]

Route	Dose	CL (mL/h)	V (mL)	F_gavage	F_chow	IIV CL	IIV V	IIV F_gavage	IIV F_chow	Proportional Residual Error
i.g.	22.22 mg/kg	83.3	791	1 FIXED	/	106.8	96.7	0	/	58.0
Daily diet	0.09% diet	83.3 FIXED	791 FIXED	1 FIXED	0.409	0	0	145	103	82.6

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male ICR mice aged 5 weeks old^[1]
Dosage:

Diet containing 0.6%
Administration:

Feed administration; 48 h
Result:

Elevated the level of liver nuclear proteins that bind to an AP-1 consensus oligonucleotide at 24 h of administration.
Induced c-Jun phosphorylation within 8 h of administration, and phosphorylated ATF-2 was detected after 24 h of administration.

Animal Model:

Female mice (Crl: CD1) aged 5 weeks old^[2]
Dosage:

Diet containing 0.025%, 0.1%, and 0.4%
Administration:

Feed administration; from 5 to 12 weeks of age.
Result:

Had no significant effect on the average body weight of female mice through the experimental periods.
Had no significant effect on the performance of multiple-T water maze at 10 weeks of age.
Reduced the average speed in a dose-dependent manner in exploratory behaviour examination at 8 weeks of age.
Shortened the total exploration distance in a dose-dependent manner and decreased the average speed in exploratory behavior examination at 11 weeks of age.

Chemical Information

CAS. Nr. 51-03-6
Appearance Oil
Molecular Weight 338.44
Formel C₁₉H₃₀O₅
Color Colorless to light yellow
SMILES

CCCC1=C(COCCOCCOCCCC)C=C2OCOC2=C1
Synonyms

ENT-14250
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Insect Sci

Fungi on the cuticle surface increase the resistance of Aedes albopictus to deltamethrin. [Abstract]

2025 Jan 19. PMID: 39828985

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (295.47 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 100 mg/mL (295.47 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9547 mL

14.7737 mL

29.5473 mL

5 mM

0.5909 mL

2.9547 mL

5.9095 mL

10 mM

0.2955 mL

1.4774 mL

2.9547 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (598 KB)
- English - EN (598 KB)
- Français - FR (598 KB)
- Deutsch - DE (598 KB)
- Norwegian - NO (598 KB)
- Español - ES (598 KB)
- Swedish - SV (598 KB)
- Italian - IT (598 KB)
- Korean - KR (598 KB)
- Portuguese - PT (598 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Muguruma M, et al. Piperonyl butoxide activates c-Jun and ATF-2 in the hepatocytes of mice. Arch Toxicol. 2008 Oct;82(10):749-53. [Content Brief]

[2]. Tanaka T, et al. Effects of piperonyl butoxide on exploratory behaviour in female mice. Toxicol Ind Health. 2019 Apr;35(4):314-323. [Content Brief]

[3]. Takahashi O, et al. Chronic toxicity studies of piperonyl butoxide in CD-1 mice: induction of hepatocellular carcinoma. Toxicology. 1997 Dec 26;124(2):95-103. [Content Brief]

[4]. Jenkins AE, et al. Pharmacokinetic analysis of acute and dietary exposure to piperonyl butoxide in the mouse. Toxicol Rep. 2023 Sep 23;11:310-317. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	2.9547 mL	14.7737 mL	29.5473 mL	73.8683 mL
	5 mM	0.5909 mL	2.9547 mL	5.9095 mL	14.7737 mL
	10 mM	0.2955 mL	1.4774 mL	2.9547 mL	7.3868 mL
	15 mM	0.1970 mL	0.9849 mL	1.9698 mL	4.9246 mL
	20 mM	0.1477 mL	0.7387 mL	1.4774 mL	3.6934 mL
	25 mM	0.1182 mL	0.5909 mL	1.1819 mL	2.9547 mL
	30 mM	0.0985 mL	0.4925 mL	0.9849 mL	2.4623 mL
	40 mM	0.0739 mL	0.3693 mL	0.7387 mL	1.8467 mL
	50 mM	0.0591 mL	0.2955 mL	0.5909 mL	1.4774 mL
	60 mM	0.0492 mL	0.2462 mL	0.4925 mL	1.2311 mL
	80 mM	0.0369 mL	0.1847 mL	0.3693 mL	0.9234 mL
	100 mM	0.0295 mL	0.1477 mL	0.2955 mL	0.7387 mL

Keywords

Piperonyl butoxide

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Piperonyl butoxide

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Anti-Liver Cancer Compound Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Environmental Pollutant Compound Library

Publications Citing Use of MedChemExpress (MCE) Piperonyl butoxide

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Piperonyl butoxide

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antiparasitic Compound library

Anti-Liver Cancer Compound Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Environmental Pollutant Compound Library

Publications Citing Use of MedChemExpress (MCE) Piperonyl butoxide

Alle Parasite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Piperonyl butoxide Related Classifications

HY-B1198 Related Classifications